Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLORPRES vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Clonidine: hepatic metabolism (CYP2D6); Chlorthalidone: excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 90% bound to plasma proteins, primarily albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.8-1.0 L/kg, indicating extensive tissue distribution; higher Vd may correlate with prolonged effect.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability is 60-70% due to first-pass metabolism; intravenous bioavailability is 100%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Chlorthalidone is ineffective if GFR <30 m L/min; avoid use. Clonidine requires dose reduction when GFR <10 m L/min; start at 0.1 mg once daily.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce clonidine dose by 25%. Child-Pugh C: avoid or use with extreme caution; clonidine may precipitate encephalopathy.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for children; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start with clonidine 0.1 mg chlorthalidone 15 mg once daily; monitor for orthostatic hypotension, bradycardia, and electrolyte disturbances. Titrate slowly every 2 weeks.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Rebound hypertension with abrupt clonidine withdrawal,Hypokalemia due to chlorthalidone,Bradycardia and syncope,Renal impairment: monitor electrolytes
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to clonidine or chlorthalidone,Anuria,Severe bradycardia or heart block
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-sodium foods as they can counteract the antihypertensive effect. Limit alcohol intake. Chlorthalidone may cause potassium depletion; consider potassium-rich foods (bananas, oranges, spinach) unless contraindicated. Grapefruit juice may increase clonidine levels; avoid excessive intake.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Pregnancy Category C. First trimester: risk of fetal bradycardia, oligohydramnios, and growth restriction due to reduced placental perfusion. Second/third trimester: potential for neonatal hypotension, respiratory depression, and electrolyte disturbances. Avoid use in pregnancy unless benefit outweighs risk.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted in breast milk. M/P ratio not established. Monitor infant for bradycardia, hypotension, and hypoglycemia. Use caution; alternative agents preferred.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Dose adjustments may be required due to increased plasma volume and metabolism. Start at lowest effective dose; titrate based on blood pressure response and fetal status. No established specific dose changes.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Clorpres (clonidine + chlorthalidone) combines central alpha-2 agonist with thiazide diuretic. Monitor for orthostatic hypotension, especially in elderly. Rebound hypertension upon abrupt clonidine discontinuation is dangerous; taper over 2-4 days. Chlorthalidone may cause hypokalemia; check potassium levels regularly. Avoid use in patients with history of depression or severe bradycardia.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take the medication exactly as prescribed, usually once daily in the morning to prevent nighttime urination.,Do not stop taking this medication suddenly; stopping abruptly can cause a severe rise in blood pressure.,Rise slowly from sitting or lying down to prevent dizziness or fainting.,Avoid alcohol, which can worsen side effects like dizziness and drowsiness.,Report signs of low potassium (muscle cramps, weakness, irregular heartbeat) or dehydration (excessive thirst, dry mouth, dark urine).
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLORPRES vs ALDORIL D30, answered by our medical review team.
CLORPRES is a Antihypertensive Combination that works by CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLORPRES and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLORPRES is: One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLORPRES and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLORPRES is classified as Category C. Pregnancy Category C. First trimester: risk of fetal bradycardia, oligohydramnios, and growth restriction due to reduced placental perfusion. Second/third trimester: potential for . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.